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Abstract: Oxidative stress in heart failure or during ischemia/reperfusion occurs as a result of the exces-
sive generation or accumulation of free radicals or their oxidation products. Free radicals formed during 
oxidative stress can initiate lipid peroxidation, oxidize proteins to inactive states and cause DNA strand 
breaks. Oxidative stress is a condition in which oxidant metabolites exert toxic effects because of their in-
creased production or an altered cellular mechanism of protection. In the early phase of acute heart ischemia cytokines 
have the feature to be functional pleiotropy and redundancy, moreover, several cytokines exert similar and overlapping ac-
tions on the same cell type and one cytokine shows a wide range of biological effects on various cell types. Activation of 
cytokine cascades in the infarcted myocardium was established in numerous studies. In experimental models of myocar-
dial infarction, induction and release of the pro-inflammatory cytokines like TNF- (Tumor Necrosis Factor ), IL-1 (In-
terleukin-1) and IL-6 (Interleukin-6) and chemokines are steadily described. The current review examines the role of 
oxidative stress and pro-inflammatory cytokines response following acute myocardial infarction and explores the inflam-
matory mechanisms of cardiac injury. 
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INTRODUCTION 
 Myocardial infarction remains the greatest killer in the 
Western world, and is the leading cause of chronic heart fail-
ure [1]. Although early reperfusion is the only way to sal-
vage an ischemic organ, during the crucial early moments of 
reperfusion, significant reversible and irreversible organ 
damage is initiated, and is referred to as reperfusion injury. 
Reperfusion injury includes arrhythmias, transient mechani-
cal dysfunction of the heart or “myocardial stunning”, mi-
crovascular injury and ‘‘no-reflow’’, as well as inflammatory 
responses. In reperfusion, cell death can occur due to apopto-
sis, necrosis, and autophagy [2-8]. Reperfusion therapy must 
be performed as soon as possible after myocardial infarction 
in order to attenuate the ischemic injury. However, reperfu-
sion is responsible for additional myocardial damage. One 
hypothesis is that antioxidants are extensively consumed 
during infarction and O2 abruptly increases metabolism after 
reperfusion in the absence of normal defenses [9]. This hy-
pothesis has led to the proposal of myocardial anti-oxidative 
conditioning. However, although several studies have re-
ported on the beneficial effect of certain antioxidants, this 
has been refuted by others [10-14], but supported by studies 
involving cardiac surgery [12, 15]. Furthermore, several re-
searches demonstrated that inflammatory processes are  
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involved in cardiovascular injury resulting from ischemia 
and/or reperfusion, thrombosis, and infection [16, 17]. For ex-
ample, myocardial inflammation has been implicated as a sec-
ondary injury mechanism after ischemia and reperfusion [18]. 
 Activation of cytokine cascades in the infarcted myocar-
dium was established in numerous studies [19-21]. In experi-
mental models of myocardial infarction, induction and release 
of the pro-inflammatory cytokines like TNF- (Tumor Necro-
sis Factor ), IL-1 (Interleukin-1) and IL-6 (Interleukin-6) 
are steadily described [21-23]. The inflammatory response is a 
multifaceted system made by many components and their in-
teractions, the inflammatory molecules and pathways are 
closely related and change cellular physiology, leading to 
various pathologies in the cardiovascular system [16, 17]. In-
flammation is also a major component of the damage caused 
by infectious diseases such as myocarditis and rheumatic heart 
disease and is also a fundamental contributor to atherosclero-
sis, ischemic heart disease, and heart failure, as well as trans-
plant vasculopathy and stroke [16].  
 Cytokines have the feature to be functional pleiotropy 
and redundancy, moreover, several cytokines exert similar 
and overlapping actions on the same cell type and one cyto-
kine shows a wide range of biological effects on various cell 
types [24]. The multifunctional, overlapping and often con-
tradictory effects of the cytokines have hindered understand-
ing of their functional role in cardiac injury and repair. In the 
infracted area is present a marked cytokine upregulation due 
to various mechanisms like Reactive Oxygen Species (ROS) 
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generation, complement activation, and NF-B (nuclear fac-
tor kappa-light-chain-enhancer of activated B cells) activa-
tion potently stimulate cytokine mRNA (Messenger Ribonu-
cleic acid) synthesis in both resident and blood-derived cells 
[25]. 
 The current review examines the role of oxidative stress 
and pro-inflammatory cytokines response following acute 
myocardial infarction and explores the inflammatory mecha-
nisms of cardiac injury. 
1. OXIDATIVE STRESS 
1.1. Free Radicals and Oxidative Stress 
 Oxidative stress in heart failure or during ische-
mia/reperfusion occurs as a result of the excessive generation 
or accumulation of free radicals or their oxidation products. 
Free radicals formed during oxidative stress can initiate lipid 
peroxidation, oxidize proteins to inactive states and cause 
DNA (Deoxyribonucleic acid) strand breaks [26]. Free radi-
cals are molecules and atoms with unpaired electrons in their 
outer shell. They are highly reactive and are formed in proc-
esses that involve oxygen. Free radicals that originate from 
oxygen are called Reactive Oxygen Species (ROS), whereas 
free radicals that originate from the reaction of oxygen with 
nitrogen are considered a subclass of free radicals and are 
called reactive nitrogen species (RNS).  
 In the case of oxygen, its univalent reduction leads to the 
formation of superoxide (.O2-) anion, which serves a key role 
in the generation of other more reactive species such as hy-
droxyl (.OH) radical. The .OH radical can be formed by two 
pathways: 1) the hydrogen peroxide (H2O2) spontaneously 
combined to form molecular oxygen, OH- and .OH radicals; 
2) the Fenton reaction where H2O2 accepts an electron from a 
reduced metal ion such as Fe2+. Superoxide serves a critical 
role here as well since it is the primary reducing agents to 
replenish the reduced metal ion. The high reactivity of the 
.OH radical causes it to react at diffusion-limited rates, and it 
reacts with the first molecule it comes into contact such as 
unsaturated fatty acid side chains resulting in lipid peroxida-
tion and disruption of cell membranes [27, 28]. Singlet oxy-
gen (1O2), the electronically excited state of molecular oxy-
gen is one of its more reactive and toxic forms. The activa-
tion of molecular oxygen to that energetic state with anti-
parallel spin (singlet state) requires overcoming of spin re-
striction. Singlet oxygen has a non-radical and electrophilic 
character. Thus, 1O2 can induce oxidative reactions with or-
ganic compounds in its electron-rich moieties without the 
participation of free radicals. The high reactivity of 1O2 with 
biological macromolecules makes it a potential aggressor 
when produced within the cell. This has been observed spe-
cially by its ability to damage guanine components and nu-
cleic acids, with toxic and mutagenic effects [29]. Mecha-
nisms for the enzymatic formation of 1O2 have been pro-
posed to occur in several cases, including as part of the host 
immune defenses in inflammatory processes. It is believed 
that different cellular types, such as eosinophils, macro-
phages and neutrophils can generate this oxidant in response 
to inflammation [30, 31]. RNS are another group of free 
radicals generated during ischemia-reperfusion from an iron-
independent reaction involving the interaction of .O2- and the 
nitric oxide (NO). RNS include nitric oxide (NO), nitrogen 
dioxide (NO2) and peroxynitrite (ONOO), the latter being 
originated by a reaction of O2. with NO [32]. Such RNS 
may have biologic activities distinct from those of the parent 
molecules [33-41]. In particular, in a biological system 
where O2 or superoxide are present, NO may be considered a 
reactive radical, when involved in the so-called “indirect 
effects” while NO “direct effects” are defined as those reac-
tions occurring between NO and specific biological mole-
cules [40]. During reperfusion a large burst of NO is pro-
duced primarily from nitric oxide synthase (NOS). In the 
same time frame large amounts of O2. are also generated. 
The overwhelming affinity of NO and O2. ensures their 
rapid reactivity during the initial moment of reperfusion to 
form ONOO [42]. One of proposed mechanisms of cardiac 
dysfunction in heart failure is the excessive production of 
NO in the heart, especially in myocytes [43]. Circulatory 
proinflammatory cytokines found in high concentrations in 
plasma of patients with heart failure [44] stimulate the ex-
pression of inducible NOS, with consequent over-production 
of NO. NO has negative inotropic effects and induces apop-
tosis at high concentrations in vitro [45]. 
 Hydrogen peroxide (H2O2), which is not a free radical, is 
considered with ROS because it is very reactive. It can be 
formed from superoxide anion and can generate hydroxyl 
radicals. In fact, strong oxidants are produced through Fen-
ton-type reactions of H2O2 with transition metal complexes 
[2, 33-41]. 
 Oxidative stress occur when there is “an increased gen-
eration of superoxide anion and hydrogen peroxide which 
overwhelms the normal cellular defence mechanisms” [46] 
and this results in oxidative damage. By their nature ROS 
can attack all cellular targets nonspecifically causing altera-
tion of membrane integrity and permeability. ROS also dena-
ture proteins determining a loss in enzyme activity. As well 
as this they interfere with the sarcoplasmic reticulum cal-
cium transport and potentiate inflammatory responses by 
acting as chemotactic agents. Unbalanced cellular redox 
status can impair signal transduction protein synthesis, en-
zyme activation and even regulation of the cell cycle [28, 47, 
48]. Alteration in membrane proteins by free radicals is 
among the important factors in the evolution of myocardial 
ischemia/reperfusion damage; oxygen free radicals can at-
tack subcellular structures resulting in metabolic and struc-
tural changes leading ultimately to apoptosis and necrosis 
[26]. 
1.2. Sources of Free Radicals, Myocardial Oxidative 
Damage, and Antioxidant Defence Systems 
 Oxidative stress is a condition in which oxidant metabo-
lites exert toxic effects because of their increased production 
or an altered cellular mechanism of protection. The heart 
needs oxygen but it is also susceptible to oxidative stress, 
which occurs during post-ischaemic reperfusion, for exam-
ple. Ischaemia causes alterations in the defence mechanisms 
against oxygen free radicals; at the same time, production of 
oxygen free radicals increases. Several possible sources of 
free radicals in the myocardium are described [3] and the 
mitochondria, myocardial cell membranes and endothelial 
cells are all potential sites of free radical production [42, 49, 
50]. These sources included: the enzymes xanthine oxi-
28    Current Vascular Pharmacology, 2015, Vol. 13, No. 1 Neri et al. 
doreductase, the major source of superoxide in postischemic 
tissue [11]; NADPH oxidase (multisubunit membrane com-
plexes), NO synthases and mitochondrial cytochromes [33-
41, 51, 52]. The mitochondria are considered the main 
source of ROS in myocardium [3] and they can produce
ROS from respiratory complex, Monoamine oxidase and 
p66Shc [52]. Their role during ischemia/reperfusion is par-
ticularly critical because of the conditions that promote both 
apoptosis by the mitochondrial pathway and necrosis by ir-
reversible damage to mitochondria in association with mito-
chondrial permeability transition (MPT). MPT is caused by 
the opening of permeability transition pores in the inner mi-
tochondrial membrane, leading to matrix swelling, outer 
membrane rupture, release of apoptotic signaling molecules 
such as cytochrome c from the intermembrane space, and 
irreversible injury to the mitochondria. During ischemia, 
factors such as intracellular Ca2+ accumulation, long-chain 
fatty acid accumulation, and ROS progressively increase 
mitochondrial susceptibility to MPT, increasing the likeli-
hood that MPT will occur on reperfusion [53]. Other poten-
tial source of oxygen radicals include superoxide anion pro-
duction from autoxidation of catecholamines via adreno-
chrome formation and from activated neutrophils. ROS, 
which are known to generate oxidative stress and produce 
cardiotoxic effects, including arrhythmias, are formed during 
the oxidation of catecholamines; the levels of catecholamines 
which are abundantly released from the ischemic myocar-
dium are increased in plasma during ischemia and subse-
quently their autoxidation could provide ROS trough the 
formation of adrenochromes and potentially induces myo-
cardial damage [54-58]. The oxidation products of catecho-
lamines have been demonstrated to produce subcellular al-
terations, intracellular Ca2+-overload, coronary spasm, myo-
cardial cell damage, depletion of high energy stores, and 
ventricular arrhythmiasm [59]. Because intracellular Ca2+-
overload is known to activate different proteases and phos-
pholipases, it is likely that the cardiotoxic effects of high 
concentrations of catecholamines may be occurring upon the 
disruption of some proteins, which control subcellular func-
tions, and/or accumulation of some phospholipids intermedi-
ates, which affect cardiac rhythms adversely [60, 61]. 
 The superoxide anion can also be produced from the cy-
clooxygenase pathway of arachidonic acid metabolism dur-
ing ischemia [49, 50, 54, 62]. In fact, calcium activation of 
phospholipases degrades cell membrane phospholipids that 
releases arachidonic acid. This is metabolized via cyclooxy-
genase and lipooxygenase to prostaglandins and leukutrie-
nes. These metabolic patways involve electron transfer that 
can initiate the formation of free radicals [28, 49, 50, 63, 64]. 
Activated neutrophils during reperfusion represent a poten-
tial source of ROS. The inflammatory response to ischemia-
reperfusion cause the release of substances with chemotactic 
activity that induces neutrophils infiltration and activation. 
They then adhere to injured endothelium where they initiate 
the production of ROS via NADPH oxidase on their cell 
membrane, which reduces molecular oxygen to superoxide 
anion and oxidize NADPH to NADP+ [28, 62, 65]. ROS 
generated during the early stages of post ischemic reperfu-
sion can induce lipid peroxidation and oxidative injury that 
result in alteration of membrane permeability and membrane 
lipid bilayer disruption. ROS also denature proteins causing 
a loss of normal enzyme activity [28, 47, 48, 66]. In addition, 
alterations in myocyte function due to oxidative stress are 
associated with the effects of free radicals on subcellular 
organelles. ROS have been involved in contractile dysfunc-
tion and hypercontracture. They have been shown to disrupt 
sarcolemma and ATPase Ca2+ transport activity and subse-
quently to induce Ca2+ overload and impair sarcoplasmic 
reticulum function [63, 67]. The critical role of intracellular 
Ca2+overload in the genesis of myocyte dysfunction has been 
well established [68]. In general, Ca2+-overload can be in-
duced by direct effect of ROS on Ca2+-handling proteins or 
indirectly, by inducing membrane lipid peroxidation. In addi-
tion, other mechanisms involving an increase in the concen-
tration of Na+ and accumulation of long chain fatty acids in 
cardiac membranes should be considered. Deficiency in ATP 
in the ischemic heart may also impair Ca2+-handling mecha-
nisms in the sarcolemmal and sarcoplasmic reticular mem-
branes and thus induce Ca2+-overload. Reperfusion of the 
ischemic heart may also increase the uptake of extracellular 
Ca2+into the myocardium and thus be another factor for Ca2+-
overload. Intracellular Ca2+-overload seems to be a common 
denominator for vasoconstriction for the development of 
hypertension, myocardial cell damage observed in ischemia-
reperfusion, and cardiac hypertrophy in heart failure [69]. 
 Exposure to free radicals from a variety of sources has 
led organisms to develop a series of defence mechanisms. 
Defence mechanisms against free radical-induced oxidative 
stress in the heart involve enzymatic and non-enzymatic an-
tioxidant defences. Enzymatic antioxidant defences include 
superoxide dismutase (SOD), glutathione peroxidase (GPx), 
catalase (CAT). Non-enzymatic antioxidants are represented 
by ascorbic acid (Vitamin C), -tocopherol (Vitamin E), glu-
tathione (GSH), carotenoids, coenzyme Q, thioredoxins. Un-
der normal conditions, there is a balance between both the 
activities and the intracellular levels of these antioxidants. 
The major thiol antioxidant and redox buffer of the cell is the 
tripeptide, GSH [70]. The oxidised form of glutathione is 
GSSG, glutathione disulphide. Oxidised glutathione is ac-
cumulated inside the cells and the ratio of GSH/GSSG is a 
good measure of oxidative stress of an organism. Too high a 
concentration of GSSG may damage many enzymes oxida-
tively. The main protective roles of glutathione against oxi-
dative stress are [70] to take part as a cofactor of several de-
toxifying enzymes against oxidative stress; to scavenge hy-
droxyl radical and singlet oxygen directly, detoxifying hy-
drogen peroxide and lipid peroxides by the catalytic action of 
glutathione peroxidase; to regenerate the most important 
antioxidants, Vitamins C and E, back to their active forms. 
The capacity of glutathione to regenerate the most important 
antioxidants is linked with the redox state of the glutathione 
disulphide-glutathione couple (GSSG/2GSH) [71]. The most 
important antioxidative enzymes of the heart are SOD, CAT 
and GPx. SOD catalyzes the dismuation of O2. to hydrogen 
peroxide (H2O2). Catalase and peroxidase remove H2O2 and, 
moreover, GPx can reduce lipid peroxides. Under normal 
conditions an equilibrium exists between the formation and 
removal ROS. If ROS are formed in excess or the defensive 
antioxidative mechanism are inefficient, oxidative stress 
develops [3, 69]. Free radical-scavenging enzymes such as 
SOD and CAT are the first line of cellular defense against 
oxidative injury, decomposing O2. and H2O2 before interact-
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ing to form the more reactive hydroxyl radical (·OH) [11, 72] 
showed that CAT activity significantly increased after reper-
fusion, suggesting that the antioxidant defense system pro-
tects the cell against reactive species. High levels of SOD 
and CAT were found in patients with coronary heart disease 
by Weinbrenner et al. [73] and Kesavulu et al. [74], respec-
tively. Bagatini et al. [75], also observed an increase in SOD 
and CAT activities in whole blood of myocardial infarction 
patients. A possible explanation for this is that the rise in 
SOD and CAT activity could be a compensatory mechanism 
to prevent tissue damage caused by oxidative stress [74]. 
Conversely, Senthil et al. [76] and Pandey et al. [77] ob-
served decreasing SOD and CAT activities in erythrocytes of 
cardiogenic shock patients and in human blood platelets in 
myocardial infarction. These findings may be explained by a 
decrease in antioxidant enzymes followed by an increase in 
their activity levels after ROS generation, such as in myo-
cardial injury followed by reperfusion [78]. Another point to 
be discussed here is that SOD and CAT are intracellular en-
zymes that can also increase due to tissue damage in myo-
cardial infarction. In the same line of thought, Nikolic-
Heitzler et al. [79], studying oxidative stress in myocardial 
infarction patients treated by percutaneous coronary inter-
vention, found an increase in antioxidant capacity, and this 
rise was assigned to the release of intracellular antioxidants 
caused by tissue damage in myocardial infarction (Fig. 1). 
2. PRO-INFLAMMATORY CYTOKINES AFTER 
MYOCARDIAL INFARCTION 
2.1. TNF-
 TNF- belongs to a superfamily of ligand/receptor pro-
teins called the tumor necrosis factor/tumor necrosis factor 
receptor superfamily proteins (TNF/TNFR SFP). TNF-
possess a trimeric symmetry with a structural motif called 
the TNF homology domain (THD), which is shared with all 
other members of the TNF proteins. This THD binds to the 
cysteine-rich domains (CRDs) of the TNF receptors 
(TNFRs), and variations of these CRDs lead to heterogeneity 
of the TNFRs [80]. TNFRs are either constitutively ex-
pressed (TNFR1, p55-R) or inducible (TNFR2, p75-R) [81]. 
 TNF- is able of exerting diverse effects on all cell types 
implicated in cardiac injury and repair. TNF- improves car-
diomyocyte apoptosis [82]. Suppresses cardiac contractility 
[83, 84] and stimulates expression of chemokines, proin-
flammatory cytokines and adhesion molecules by endothelial 
cells and leukocytes, in addition regulates extracellular ma-
trix metabolism, in cardiac fibroblasts, by enhancing Matrix 
metalloproteinases activity and by decreasing collagen syn-
thesis [85].  
 Various studies tried to explain the diverse effects of 
TNF- in the infarcted myocardium. Sun et al. demonstrated 
that elevated local TNF- in the infarcted myocardium con-
tributes to acute myocardial rupture and chronic left ventricle 
dysfunction by inducing exuberant local inflammatory re-
sponse, matrix and collagen degradation, increased matrix 
metalloproteinase activity, and apoptosis [86]. 
 Several other studies have demonstrated an essential role 
for TNF- in mediating inflammatory injury following in-
farction [23, 87]. 
 Contradictory findings regarding the effects of TNF-
neutralization on the infarcted heart were found in inhibition 
studies. Several studies demonstrated injurious effects of 
TNF- signaling in mediating infarct expansion and cardiac 
Fig. (1). Role of oxidative stress and antioxidant defense in the heart following ischemia/reperfusion. 
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dysfunction. In particular Berthonneche et al. demonstrated 
that TNF- plays a major role in cardiac alterations 7 days 
after myocardial infarction in rats and contributes to hemo-
dynamic derangement, but not to cardiac remodeling, in sub-
sequent Cardiac Heart Failure [88] and Sugano et al. proved 
that the suppression of TNF-alpha bioactivity from the early 
stage of infarction with the Soluble TNF-alpha receptor 1 
plasmid improved cardiac function and reduced infarct size 
[89]. 
 While other authors indicated protective effects of TNF-
signaling in the infarcted myocardium. Moden et al. demon-
strated that the TNF- inhibition using gene therapy with 
soluble TNF alpha receptor had deleterious effects in a 
mouse infarction model promoting cardiac rupture and en-
hancing adverse remodeling [90]. 
 In addition, Kurrelmeyer et al. in an animal experimental 
study showed that the peak frequency and extent of apoptosis 
were accelerated in the TNFR1/TNFR2-deficient mice when 
compared with the wild-type mice. The increase in apoptosis 
in the TNFR1/TNFR2-deficient mice did not appear to be 
secondary to a selective up-regulation of the Fas ligand/ 
receptor system in these mice. These data suggest that TNF 
signaling gives rise to one or more cytoprotective signals that 
prevent and/or delay the development of cardiac myocyte 
apoptosis after acute ischemic injury [91].  
 The results of these studies showed that TNF- may in-
duce cytoprotective signals able of preventing or delaying 
the development of myocyte apoptosis after myocardial in-
farction. TNF- may exercise distinct biological effects 
through the TNFR1 and TNFR2 receptor. Monden et al.
suggest that effects mediated through TNFR1 are harmful, 
inducing cardiac dysfunction, whereas TNFR2-mediated 
actions may be protective by attenuating adverse remodeling 
[92].  
 In a recent study, Yu et al. investigated direct effects of 
hypoxia on TNF- expression of cardiomyocytes, the role of 
hypoxia inducible factor-1 (HIF-1) in TNF- regulation 
and potential secretory pathway of TNF-. Elevated TNF-
expression and HIF-1 activation in primary cultured car-
diomyocytes under hypoxia were detected by real-time PCR, 
Western blotting and immunofluorescence. Results of this 
study indicate that under hypoxia, HIF-1 initiates expres-
sion of TNF-, mediated by exosomes in cardiomyocytes 
[93]. 
 The contradictory findings of the various studies about 
the role of TNF- in myocardial infarction highlight the 
complex and pleiotropic actions of the cytokines in biologi-
cal processes and may explain the unpredictable effects of 
cytokine-targeted therapeutic strategies in clinical trials for 
example the clinical significance of early TNF- elevation in 
patients ST-segment elevation myocardial infarction 
(STEMI) and successful primary percutaneous coronary in-
tervention (PCI) [94]. 
2.2. IL-1 Family 
 The Interleukin-1 (IL-1) gene family consists of three 
members: IL-1, IL-1 and IL-1 receptor antagonist (IL-
1ra). IL-1 and IL-1 play an agonist role, while IL-1ra is a 
specific receptor antagonist [95].  
 IL-1 and IL-1 are able to induce the release and func-
tion of chemokines, growth factors, other cytokines, and 
adhesion molecules. In several experimental models of myo-
cardial infarction has been demostreted an upregulation of 
IL-1 and IL-1 [19, 96]. 
 In patients affected by acute myocardial infarction has 
been recorded, a significant increase of IL-1 plasma levels 
[97]. Suzuki et al. demonstrated that IL-1ra introduced by 
gene transfection protected myocardium from ischemia-
reperfusion injury by attenuating the inflammatory response, 
which was associated with decreased apoptosis. This sug-
gests a potentially important role of IL-1/IL-1ra in myocar-
dial ischemia-reperfusion injury and the value of IL-1ra-gene 
therapy for myocardial preservation; so, this study advances 
an injurious role for IL-1 in the ischemic myocardium [98]. 
 In opposition of the study of Suzuki et al. another inves-
tigation performed by Hwang et al. suggested a protective 
role of IL-1 in myocardial infarction demonstrating that IL-
1 neutralization in the acute phase of myocardial infarction 
caused an increase of cardiac rupture and enhanced adverse 
remodeling [99]. 
 The proinflammatory cytokine interleukin IL-1 signals 
exclusively through the type I IL-1 receptor (IL-1RI). IL-1 
expression is markedly induced in the infarcted heart; how-
ever, its role in cardiac injury and repair remains controver-
sial [100]. Following reperfused infarction IL-1RI null mice 
exhibited decreased infiltration of the infarcted myocardium 
with neutrophils and macrophages and reduced chemokine 
and cytokine expression. IL-1 signaling is essential for acti-
vation of inflammatory and fibrogenic pathways in the heal-
ing infarct, playing an important role in the pathogenesis of 
remodeling after infarction. Thus, interventional therapeutics 
targeting the IL-1 system may have great benefits in myo-
cardial infarction [100, 101].
 Different studies have identified a role of IL-1 in the de-
velopment of adverse cardiac remodeling. However, in ani-
mal models of Acute myocardial infarction IL-1 has been 
shown to be cardioprotective in preconditioning, raising the 
question of clinical safety of therapeutic IL-1 blockade for 
autoinflammatory diseases or for the prevention or the treat-
ment of Acute myocardial infarction. Toldo et al. proposed 
to evaluate the effects of pretreatment with recombinant hu-
man interleukin-1 receptor antagonist (rhIL-1Ra) on ische-
mia reperfusion (I/R) injury to the heart and showed that IL-
1 blockade therapies using rhIL-1Ra prior the onset of Acute 
myocardial infarction protects the myocardium and preserves 
cardiac function in an animal model [102].
2.3. The IL-6 Family of Cytokines 
 The family of IL (interleukin)-6-type cytokines com-
prises IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM 
(oncostatin M), CNTF (ciliary neurotrophic factor), CT-1 
(cardiotrophin-1) and CLC (cardiotrophin-like cytokine) and 
neurotrophin-1/B-cell stimulating factor-3 (NNT-1/BSF-3). 
They activate target genes involved in differentiation, sur-
vival, apoptosis and proliferation. The members of this cyto-
kine family have pro- as well as antiinflammatory properties 
and are major players in haematopoiesis, as well as in acute-
phase and immune responses of the organism. All IL-6-
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related cytokines signal through multisubunit receptors that 
share the transmembrane glycoprotein (gp)130. Many ex-
perimental studies demonstrated induction of members of the 
IL-6 family in healing infarcts [103].  
 In the ischemic myocardium, the IL-6 synthesis is 
quickly induced in mononuclear cells and cardiomyocytes 
[23, 104, 105]. 
 In fibroblasts and surviving cardiomyocytes the Car-
diotrophin-1 is upregulated and manifests a delayed period 
of expression [103, 106], while LIF [22] and oncostatin-M 
[107] are induced during the inflammatory phase of healing.  
 Despite the numerous studies performed the functional 
role of IL-6 in infarct healing remains unknown. Members of 
the IL-6 family have intense effects on cardiac myocytes 
both in the protection from apoptosis and promotion of car-
diac hypertrophy [108].  
 CT-1 can protect adult cardiac cells both in vitro and in 
vivo when added both prior to or after the hypoxic/ischemic 
stimulus. CT-1 administration resulted in decreased infarct 
size and reduced cardiomyocyte apoptosis in a rat model of 
myocardial ischemia and reperfusion [109]. In a mouse 
model of reperfused infarction, CT-1 absence did not modi-
fied infarct size, so the study suggest that endogenous CT-1 
does not play an essential role in acute ischemic cardiac in-
jury [110]. While a prolonged CT-1 upregulation in the in-
fracted myocardium may modulate the fibrotic response 
through effects on fibroblast proliferation [111]. 
 The role of endogenous LIF expression in the infarct re-
mains is not well known, LIF enhances survival of cardio-
myocytes and induces regeneration of myocardium after 
myocardial infarction and induced angiogenesis, improving 
recruitment of bone marrow-derived cells into the heart 
[112]. 
 IL-6 is able of modulating the phenotypic characteristics 
and gene expression of many cell types involved in infarct 
healing [113]. However, Fuchs et al. [114] found that the 
absence of IL-6 did not affect infarct size, left ventricular 
function and post-infarction remodeling in non-reperfused 
infarcts.  
2.4. The Chemokine Family in Myocardial Infarction 
 Chemokines are a family of small cytokines, or proteins 
(8-14 kDa) secreted by cells with a strikingly similar tertiary 
structure. Their name is derived from their ability to induce 
directed chemotaxis in nearby responsive cells; they are 
chemotactic cytokines. Proteins are classified as chemokines 
according to shared structural characteristics such as small 
size, and the presence of four cysteine residues in conserved 
locations that are key to forming their 3-dimensional shape 
[115]. Chemokines are divided into subfamilies on the basis 
of the number and sequential relationship of their conserved 
cysteine residues (CXC, CC, XCand CX3C subfamilies). 
The principal targets of Chemokines are bone marrow-
derived cells they have a fundamental role in basal and in-
flammatory leukocyte locomotion and trafficking [116, 117].
 Chemokines are able of eliciting a variety of responses 
concerning leukocyte activation, degranulation and apopto-
sis, in addition same studies suggests that chemokines exert 
important actions on many cell types beyond the immune 
system, including endothelial cells (resulting in angiogenic, 
or angiostatic effects), smooth muscle cells, neurons and 
epithelial cells [118].
 Chemokines can be shared in two groups: homeostatic 
chemokines (constitutively expressed in certain tissues and 
responsible of basal leukocyte trafficking), and inducible 
chemokines (upregulated by inflammatory stimuli, in the 
inflammatory reactions and inducing leukocyte recruitment) 
[119, 120].  
 The stimulus for the production of chemokines is a fun-
damental feature of the postinfarction inflammatory response 
[121-123]. 
 Variuos experimental models of myocardial infarction 
showed a strong induction of several members of the 
chemokine family in the ischemic heart supporting their role 
in leukocyte recruitment, infarct angiogenesis and fibrous 
tissue deposition [124].  
 Monocyte chemoattractant protein (MCP)-1/CCL2 is 
expressed by mainly inflammatory cells and stromal cells, 
such as endothelial cells, mediates recruitment of mononu-
clear cells, modulates monocyte and lymphocyte phenotype 
and regulates fibrous tissue deposition and angiogenesis and 
its expression is upregulated after proinflammatory stimuli 
and tissue injury. MCP-1 can function as a traditional che-
motactic cytokine and also regulates gene transcription, in-
deed MCP-1 is markedly induced in the infarcted myocar-
dium and plays an important role in infarct healing and post-
infarction remodeling [125]. In studies utilizing MCP-1 null 
mice was been demonstrated a decreasing macrophage re-
cruitment in the infarcted heart, delayed phagocytosis of 
dead cardiomyocytes, diminished fibroblast infiltration and 
attenuated left ventricular remodeling [126]. During the in-
flammatory stage of infarct healing, MCP-1 mediates 
macrophage recruitment and timely clearance of dead cells 
from the infarct; however, prolonged induction of the 
chemokine in the infarcted heart may result in extension of 
granulation tissue formation and adverse remodeling of the 
ventricle [127]. The recently identified novel zinc-finger 
protein, called MCPIP (MCP-1-induced protein), promotes a 
series of signaling events that causes oxidative and endo-
plasmic reticulum (ER) stress, leading to autophagy that can 
result in cell death or differentiation, depending on the cellu-
lar context [128] (Fig. 2). 
 The mechanisms with MCP-1 causes migration of cells 
through binding to its receptor CCR2, present on the target 
cells, has been studied extensively [129]. Various studies 
demonstrated the role of MCP-1 in a variety of inflammatory 
diseases. The signal transduction events initiated by MCP-1 
binding to CCR2 could result in induction of genes that 
could play a significant role in the development of inflamma-
tory processes, but, the genes induced by MCP-1 and their 
potential role in inflammatory processes is not well under-
stood [130, 131]. 
 Experimental studies have identified a novel CCCH zinc 
finger protein, which was significantly induced by MCP-1 in 
human monocytes and thus designated as MCP-induced pro-
tein (MCPIP), as negative regulator of macrophage activa-
tion.  
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 The scientific evidence demonstrated that MCP-1 induc-
tion of a novel class of zinc-finger proteins in human periph-
eral blood monocytes is a consequence of the chain of events 
triggered by MCP-1 binding to CCR2 [131, 132]. The MCPIP 
turned out to be the first member of a novel family of CCCH 
zinc-finger proteins containing 4 members that we designate 
MCPIP 1, 2, 3, and 4, encoded by zc3h12a, zc3h12b, zc3h12c, 
and z2ch12d, respectively.125 The best-studied member 
MCPIP1 is often simply called MCPIP. A genome-wide 
analysis of the CCCH zinc-finger gene family discovered 58 
such genes in mice and 55 in humans. At least 7 of them were 
found to be expressed in macrophage-related organs such as 
thymus, spleen, lung, intestine, and adipose tissues [133]. 
MCPIP was found to be caplable to control inflammatory re-
sponse by inhibition of nuclear factor-B activation through its 
deubiquitinase activity or by degradation of mRNA encoding a 
set of inflammatory cytokines through its RNase activity [128]. 
 In the family of chemokine, IL-8/CXCL8 is the prototypic 
of CXC chemokine, and plays a critical role in regulation of 
neutrophil influx and activation with angiogenic properties 
[134-136]. 
Fig. (2). Schematic representation of the MCP-1/MCPPIP-induced processes in myocardial infarcted. 
Fig. (3). Pro-inflammaroty cytokynes in the heart following acute ischemia. 
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 In animal models (canine and rabbit) of experimental 
myocardial infarction the IL-8 upregulation has been ex-
plained [137, 138]. IL-8 induces the neutrophil respiratory 
burst and granule release, and enhances cellular adhesion, a 
2 integrin-dependent event. The activation of 2-integrin 
induced by IL-8 may be mediated through mitogen-activated 
protein kinase (MAPK) and protein kinase C (PKC) signal-
ing. IL-8 may also have effects beyond its neutrophil chemo-
tactic properties [139]. In a rabbit model study of myocardial 
ischemia-reperfusion injury the authors showed that IL-8 
neutralization significantly reduces the degree of necrosis 
without affecting neutrophil infiltration [140] (Fig. 3). 
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